Early access
Sign in
Taking people in United StatesNo phase

Imaging inflammation in the aorta wall of people with abdominal aortic aneurysm

Tests a scan drug, 64Cu-DOTA-ECL1i, to image inflammation in abdominal aortic aneurysm.

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
Status
Recruiting
People taking part
30 people, planned
Started
30 Apr 2026
Expected to end
30 Apr 2029
Type of study
Observational, 2 groups
Treatments tested
  • 64Cu-DOTA-ECL1i
Record updated
22 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an abdominal aortic aneurysm (a bulge in the main blood vessel of the belly). It also takes people of a similar age without this aneurysm as a comparison group.

Age
18 years and older
Sex
All sexes
Disease stage
An established diagnosis of abdominal aortic aneurysm based on standard clinical criteria, or no known aneurysm for the comparison group.

Main reasons for not taking part

  • Being pregnant or breastfeeding at the time of the PET/CT scan
  • Chronic kidney disease with GFR less than 40 mL/min/1.73m² at enrollment
  • Known allergy to iodinated contrast (iodine dye used in scans)
  • Unable to go through the imaging scans
  • Life expectancy of less than 6 months

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participants will be at least 18 years of age
  • Have an established diagnosis of abdominal aortic aneurysm based on standard clinical criteria or are an age matched control with absence of known AAA
  • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures

Who cannot take part

  • Documented allergy to iodinated contrast
  • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
  • Patients with chronic renal disease whose GFR is less than 40 mL/min/1.73m² at the time of enrollment
  • Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential before the injection of radiotracer
  • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
  • Less than 6 months life expectancy as deemed by the treating physician at the time of initial enrollment

Where in United States

  • Penn Medicine; Perelman School of MedicinePhiladelphia, United StatesContact: Erin SchubertTaking people

About the trial

What the trial wants to find out

This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography).

Read full original descriptionShow less

The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.

The 2 groups in the trial

  • Participants diagnosed with Abdominal Aortic Aneurysm (AAA)

    Established diagnosis of abdominal aortic aneurysm based on standard clinical criteria.

    Treatment: 64Cu-DOTA-ECL1i

  • Control Group

    Age-matched participants without a diagnosis of AAA as a control group.

    Treatment: 64Cu-DOTA-ECL1i

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
Plain-language title
Imaging inflammation in the aorta wall of people with abdominal aortic aneurysmGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
22 May 2026